Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H, M, R | ICC, IHC, WB | Rb | Serum | Polyclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | AB9080 |
| Brand Family | Chemicon® |
| Trade Name |
|
| Description | Anti-Ryanodine Receptor 2 Antibody |
| Product Information | |
|---|---|
| Format | Serum |
| Control |
|
| Presentation | Rabbit serum. Liquid. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-Ryanodine Receptor 2 Antibody is an antibody against Ryanodine Receptor 2 for use in IC, IH & WB. |
| Key Applications |
|
| Application Notes | Western blot: 1:1,000 using ECL. The antibody reacts with the 500 kDa Ryanodine Receptor 2 protein. Suggested blocking buffer is 10% normal goat serum (or same host as your secondary antibody), 1% BSA in 0.1M PBS with 0.05% Tween 20. Suggested dilution buffer is 1% normal goat serum (or same host as your secondary antibody), 1% BSA in 0.1M PBS with 0.05% Tween 20. Preferred gel percentage is 4-12% gradient gel. Immunocytochemistry: 1:1,000 Immunohistochemistry: 1:1,000 overnight at 2-8°C using a fluorescently labeled secondary antibody. Suggested fixative is 4% paraformaldehyde in 0.1M PBS (one hour). Suggested permeablization method is 0.05% Triton X-100 in dilution buffer. Suggested blocking buffer is 10% normal goat serum (or same host as your secondary antibody) and 1% BSA in 0.1M PBS. Suggested dilution buffer is 1% normal goat serum (or same host as your secondary antibody) and 1% BSA in 0.1M PBS. Optimal working dilutions must be determined by the end user. |
| Biological Information | |
|---|---|
| Immunogen | Synthetic peptide from the variant TM region of human Ryanodine Receptor 2. |
| Host | Rabbit |
| Specificity | Ryanodine Receptor 2. |
| Species Reactivity |
|
| Antibody Type | Polyclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | This gene encodes a ryanodine receptor found in cardiac muscle sarcoplasmic reticulum. The encoded protein is one of the components of a calcium channel, composed of a tetramer of the ryanodine receptor proteins and a tetramer of FK506 binding protein 1B proteins, that supplies calcium to cardiac muscle. Mutations in this gene are associated with stress-induced polymorphic ventricular tachycardia and arrhythmogenic right ventricular dysplasia. |
| Gene Symbol |
|
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: Q92736 # Communication between transverse-tubules and sarcoplasmic reticulum. Contraction of cardiac muscle is triggered by release of calcium ions from SR following depolarization of T- tubules (By similarity). SIZE: 4967 amino acids; 564498 Da SUBUNIT: Homotetramer (Potential). SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (Probable). TISSUE SPECIFICITY: Heart muscle, brain (cerebellum and hippocampus) and placenta. DEVELOPMENTAL STAGE: Expressed in myometrium during pregnancy. DISEASE: SwissProt: Q92736 # Defects in RYR2 are the cause of familial arrhythmogenic right ventricular dysplasia 2 (ARVD2) [MIM:600996]; also known as arrhythmogenic right ventricular cardiomyopathy 2 (ARVC2). ARVD is an autosomal dominant disease characterized by partial degeneration of the myocardium of the right ventricle, electrical instability, and sudden death. It is clinically defined by electrocardiographic and angiographic criteria; pathologic findings, replacement of ventricular myocardium with fatty and fibrous elements, preferentially involve the right ventricular free wall. & Defects in RYR2 are the cause of an autosomal dominant form of stress-induced polymorphic ventricular tachycardia (VTSIP) [MIM:604772]; also known as catecholaminergic polymorphic ventricular tachycardia (CPVT). VTSIP is a genetic arrhythmogenic disorder characterized by stress-induced, bidirectional ventricular tachycardia that may degenerate into cardiac arrest and cause sudden death. & Defects in RYR2 are a cause of familial polymorphic ventricular tachycardia (FPVT) [MIM:192605]. FPVT is an autosomal- dominant, inherited disease with a relatively early onset and a mortality rate of approximately 30% by the age of 30 years. Phenotypically, it is characterized by salvoes of bidirectional and polymorphic ventricular tachycardias in response to vigorous exercise, with no structural evidence of myocardial disease. SIMILARITY: SwissProt: Q92736 ## Belongs to the ryanodine receptor family. & Contains 3 B30.2/SPRY domains. & Contains 1 EF-hand domain. & Contains 5 MIR domains. MISCELLANEOUS: The calcium release channel is modulated by calcium ions, magnesium ions, ATP and calmodulin. & The calcium release channel activity resides in the C-terminal region while the remaining part of the protein constitutes the foot structure spanning the junctional gap between the SR and the T-tubule. It is possible that the foot structure interacts with the cytoplasmic region of the dihydropyridine receptor. & Ryanodine is an alkaloid that binds to the Ca- release channel in junctional SR and modulates its activity. |
| Product Usage Statements | |
|---|---|
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Maintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles. |
| Packaging Information | |
|---|---|
| Material Size | 100 µL |